Contribution of Topoisomerase IV and DNA Gyrase Mutations in Streptococcus pneumoniae to Resistance to Novel Fluoroquinolones

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  1999-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.43.8.2000PMID 10428926PMCID PMC89404
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Destruction of low efficiency markers is a slow process occurring at a heteroduplex stage of transformation

  2004cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard

  2000cited by this paper
• Inhibition of the Emergence of Ciprofloxacin Resistance in Streptococcus pneumoniae by the Multidrug Efflux Inhibitor Reserpine

  1999cited by this paper
• Activities of Newer Fluoroquinolones against Streptococcus pneumoniae Clinical Isolates Including Those with Mutations in the gyrA, parC, and parELoci

  1999cited by this paper
• Isolation and Characterization of Three Streptococcus pneumoniae Transformation-Specific Loci by Use of alacZ Reporter Insertion Vector

  1998cited by this paper
• Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae.

  1998cited by this paper
• A new fluoroquinolone for community-acquired pneumonia.

  1998cited by this paper
• Prevalence of a Putative Efflux Mechanism among Fluoroquinolone-Resistant Clinical Isolates ofStreptococcus pneumoniae

  1998cited by this paper
• Activities of New Fluoroquinolones against Fluoroquinolone-Resistant Pathogens of the Lower Respiratory Tract

  1998cited by this paper
• Editorial Response: A New Fluoroquinolone for Community-Acquired Pneumonia

  1998cited by this paper
• The chemistry and biological profile of trovafloxacin.

  1997cited by this paper
• Primary hydatidosis of the peripheral muscles: treatment with albendazole.

  1997cited by this paper
• Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae

  1997cited by this paper
• Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae

  1997cited by this paper
• Evolving clinical problems with Streptococcus pneumoniae: increasing resistance to antimicrobial agents, and failure of traditional optochin identification in Chicago, Illinois, between 1993 and 1996.

  1997cited by this paper
• Nomenclature of TEM beta-lactamases.

  1997cited by this paper
• Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones

  1997cited by this paper
• Antibiotic resistance in Streptococcus pneumoniae.

  1997cited by this paper
• Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae

  1997influential reference
• ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype

  1996influential reference
• Concentration controlled and concentration defined clinical trials: do they offer any advantages for antimicrobial chemotherapy?

  1996cited by this paper
• Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro

  1996cited by this paper
• Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro

  1996cited by this paper
• Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae

  1996cited by this paper
• In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens.

  1996cited by this paper
• Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance

  1996cited by this paper
• Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus

  1995cited by this paper
• Antibiotic-resistance in Streptococcus pneumoniae.

  1995cited by this paper
• Isolation and characterization of three new classes of transformation-deficient mutants of Streptococcus pneumoniae that are defective in DNA transport and genetic recombination

  1983cited by this paper
• National Committee for Clinical Laboratory Standards.

  1980cited by this paper

• Modeling Rotational Fluoroquinolone Therapy as a Novel Treatment for Ophthalmic MRSA Infections

  2025cites this paper
• Detection of resistance to fluoroquinolones and injectable drugs among antituberculosis drugs by allele-specific primer extension on a microsphere-based platform.

  2018cites this paper
• Bacterial Genotypic Drug Resistance Assays

  2017cites this paper
• Emergence of quinolone-resistant strains in Streptococcus pneumoniae isolated from paediatric patients since the approval of oral fluoroquinolones in Japan.

  2017cites this paper
• Pathogenesis of microbial keratitis.

  2017cites this paper
• Whole Genome Sequencing of 39 Invasive Streptococcus pneumoniae Sequence Type 199 Isolates Revealed Switches from Serotype 19A to 15B

  2017cites this paper
• States 377 Medical Centers throughout the United against Recent Respiratory Isolates from Moxifloxacin and Comparator Agents Benchmarking the In Vitro Activities of

  2014cites this paper
• Vitro with Trovafloxacin Quinolone-Resistant Mutants Selected In and Characterization of hominis Mycoplasma

  2014cites this paper
• High prevalence of multiresistance in levofloxacin-nonsusceptible Streptococcus pneumoniae isolates in Korea.

  2013cites this paper
• Evaluación y manejo de la neumonía de la comunidad (II)

  2012cites this paper
• Tuning of antibacterial activity of a cyclopropyl fluoroquinolone by variation of the substituent at position C-8.

  2011cites this paper
• Comparison of drug sensitivity and genotypes of clinically isolated strains of levofloxacin-resistant Streptococcus pneumoniae obtained from Okinawa Island, the Japanese main island and Hong Kong

  2011cites this paper
• Management of fluoroquinolone use to avoid microbial resistance in clinical practice.

  2010cites this paper
• Genotypic Drug Resistance Assays

  2009cites this paper
• In vitro selection of resistance in Streptococcus pneumoniae at in vivo fluoroquinolone concentrations.

  2009cites this paper
• Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia

  2008cites this paper
• Streptococcus pneumoniae: An Update on Resistance Patterns in the United States

  2008cites this paper
• Mechanisms of Resistance by Gram-Positive Bacteria (Streptococci and Enterococci)

  2008cites this paper
• parE mutations in Streptococcus pneumoniae may reduce bactericidal activity of respiratory fluoroquinolones.

  2007cites this paper
• New Real-Time PCR Assay Using Locked Nucleic Acid Probes To Assess Prevalence of ParC Mutations in Fluoroquinolone-Susceptible Streptococcus pneumoniae Isolates from France

  2006cites this paper
• Approaches to treatment of community-acquired pneumonia in the emergency department and the appropriate role of fluoroquinolones.

  2006cites this paper
• Infrequent occurrence of single mutations in topoisomerase IV and DNA gyrase genes among US levofloxacin-susceptible clinical isolates of Streptococcus pneumoniae from nine institutions (1999-2003).

  2006cites this paper
• Nonmolecular Test for Detection of Low-Level Resistance to Fluoroquinolones in Streptococcus pneumoniae

  2006cites this paper
• Managing acute lower respiratory tract infections in an era of antibacterial resistance.

  2006cites this paper
• Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004).

  2006cites this paper
• In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.

  2006cites this paper
• Therapeutic options for pneumococcal pneumonia in Turkey.

  2005cites this paper
• In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.

  2005cites this paper
• Entwicklung zellulärer und molekularbiologischer Testsysteme zur Bestimmung der Aktivität von Fluorchinolonen auf Typ II-Topoisomerasen am Beispiel von Pradofloxacin - einem neuen C8-Cyanofluorchinolon

  2005cites this paper
• Characterisation of fluoroquinolone-resistant clinical isolates of Streptococcus pyogenes in Barcelona, Spain.

  2005cites this paper
• Mechanisms of antimicrobial resistance in the intensive care unit

  2005cites this paper
• The mutant-prevention concentration (MPC) : ideas for restricting the development of fluoroquinolone resistance

  2005cites this paper
• Gemifloxacin for the Treatment of Respiratory Tract Infections: In Vitro Susceptibility, Pharmacokinetics and Pharmacodynamics, Clinical Efficacy, and Safety

  2005cites this paper
• High Genetic Diversity of Ciprofloxacin-Nonsusceptible Isolates of Streptococcus pneumoniae in Poland

  2005cites this paper
• Antibiotic Selection and Outcome-Effective Management of Community-Acquired Pneumonia : Year 2004 Update

  2004cites this paper
• Fluoroquinolone Resistance in Clinical Isolates of Streptococcus pneumoniae from Asian Countries: ANSORP Study

  2004cites this paper
• [Molecular epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae in Japan].

  2004cites this paper
• Molekulare Untersuchung der Makrolid-, Tetrazyklin-, Chinolon- und Trimethoprim/Sulfamethoxazol-Resistenzmechanismen bei europäischen Streptococcus pneumoniae Isolaten

  2004influential citation
• Quinolone resistance mechanisms in pneumococci.

  2004cites this paper
• Efficacy and tolerability of moxifloxacin in the treatment of acute bacterial sinusitis caused by penicillin-resistant Streptococcus pneumoniae: a pooled analysis.

  2004cites this paper
• Gemifloxacin: A New Fluoroquinolone Approved for Treatment of Respiratory Infections

  2004cites this paper
• Mechanisms of Quinolone Action

  2003cites this paper
• Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.

  2003cites this paper
• Maintaining Fluoroquinolone Class Efficacy: Review of Influencing Factors

  2003cites this paper
• Fluoroquinolones in the treatment of meningitis

  2003cites this paper
• Fluoroquinolone Resistance in Streptococcus pneumoniae: Evidence That gyrA Mutations Arise at a Lower Rate and That Mutation in gyrA or parC Predisposes to Further Mutation

  2003cites this paper
• Fluoroquinolones: action and resistance.

  2003cites this paper
• Activities of Mutant Prevention Concentration-Targeted Moxifloxacin and Levofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model

  2003cites this paper
• MECHANISMS OF QUINOLONE RESISTANCE

  2003cites this paper
• Diversity of Ribosomal Mutations Conferring Resistance to Macrolides, Clindamycin, Streptogramin, and Telithromycin in Streptococcus pneumoniae

  2002cites this paper
• Topoisomerase Mutations Associated with In Vitro Selection of Resistance to Moxifloxacin in Streptococcus pneumoniae

  2002cites this paper
• Molecular characterization of the genes encoding DNA gyrase and topoisomerase IV of Listeria monocytogenes.

  2002cites this paper
• Selection of Streptococcus pneumoniae Mutants Having Reduced Susceptibility to Moxifloxacin and Levofloxacin

  2002cites this paper
• In Vitro Activities of Novel Nonfluorinated Quinolones PGE 9262932 and PGE 9509924 against Clinical Isolates of Staphylococcus aureus and Streptococcus pneumoniae with Defined Mutations in DNA Gyrase and Topoisomerase IV

  2002cites this paper
• Activity of Quinolones Against Gram-Positive Cocci: Mechanisms of Drug Action and Bacterial Resistance

  2002cites this paper
• Safety of fluoroquinolones: An update.

  2002cites this paper
• Resistance among Streptococcus pneumoniae: Implications for drug selection.

  2002cites this paper
• A critical review of the fluoroquinolones: focus on respiratory infections.

  2002cites this paper
• Levofloxacin Treatment Failure in a Patient with Fluoroquinolone‐Resistant Streptococcus pneumoniae Pneumonia

  2002cites this paper
• Microbiology of newer fluoroquinolones: focus on respiratory pathogens.

  2002cites this paper
• Prevalence of Single Mutations in Topoisomerase Type II Genes among Levofloxacin-Susceptible Clinical Strains of Streptococcus pneumoniae Isolated in the United States in 1992 to 1996 and 1999 to 2000

  2002cites this paper
• Fluoroquinolone-Resistant Streptococcus pneumoniae Strains Occur Frequently in Elderly Patients in Japan

  2002cites this paper
• A Critical Review of the Fluoroquinolones

  2002cites this paper
• What have we learned about antimicrobial prescribing

  2002cites this paper
• Quinolonas y Streptococcus pneumoniae. Mecanismo de acción y resistencia

  2002cites this paper
• Selection and Genetic Characterization of Streptococcus pneumoniae Mutants Resistant to the Des-F(6) Quinolone BMS-284756

  2001cites this paper
• Fluoroquinolone Resistance Is a Poor Surrogate Marker for Type II Topoisomerase Mutations in Clinical Isolates ofStreptococcus pneumoniae

  2001cites this paper
• Resistance Molecular Detection of Antimicrobial

  2001cites this paper
• Sub-inhibitory concentrations of vancomycin prevent quinolone-resistance in a penicillin-resistant isolate of Streptococcus pneumoniae

  2001cites this paper
• In Vitro Development of Resistance to Six Quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus

  2001cites this paper
• Low-level antibacterial resistance: a gateway to clinical resistance.

  2001cites this paper
• Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolones.

  2001influential citation
• Quinolone resistance: Older concepts and newer developments

  2001cites this paper
• Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity.

  2001cites this paper
• Moxifloxacin: a review of the microbiological, pharmacological, clinical and safety features

  2001cites this paper
• Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria.

  2001cites this paper
• Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118.

  2001cites this paper
• Evaluation of Susceptibility Testing To Detect Fluoroquinolone Resistance Mechanisms in Streptococcus pneumoniae

  2001influential citation
• Efflux pumps: their role in antibacterial drug discovery.

  2001cites this paper
• Mutant Prevention Concentrations of Fluoroquinolones for Clinical Isolates of Streptococcus pneumoniae

  2001cites this paper
• Penicillin-resistant streptococcus pneumoniae: review of moxifloxacin activity.

  2001cites this paper
• Molecular Detection of Antimicrobial Resistance

  2001cites this paper
• A Convenient Assay for Estimating the Possible Involvement of Efflux of Fluoroquinolones by Streptococcus pneumoniae andStaphylococcus aureus: Evidence for Diminished Moxifloxacin, Sparfloxacin, and Trovafloxacin Efflux

  2000cites this paper
• Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.

  2000cites this paper
• The fluoroquinolone antibacterials: past, present and future perspectives.

  2000cites this paper
• [Problems with gram-positive bacteria: resistance in staphylococci, enterococci, and pneumococci to antimicrobial drugs].

  2000cites this paper
• Benchmarking the In Vitro Activities of Moxifloxacin and Comparator Agents against Recent Respiratory Isolates from 377 Medical Centers throughout the United States

  2000cites this paper
• [Problem gram-positive bacteria: resistance in staphylococci, enterococci and pneumococci to antimicrobial drugs].

  2000cites this paper
• Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study.

  2000cites this paper
• Cloning and Nucleotide Sequence of the DNA Gyrase (gyrA) Gene from Mycoplasma hominis and Characterization of Quinolone-Resistant Mutants Selected In Vitro with Trovafloxacin

  2000cites this paper
• Fluoroquinolone Resistance in Clinical Isolates ofStreptococcus pneumoniae: Contributions of Type II Topoisomerase Mutations and Efflux to Levels of Resistance

  2000influential citation